{"created":"2023-06-20T15:47:24.217217+00:00","id":1939,"links":{},"metadata":{"_buckets":{"deposit":"3bce7f48-65ba-4a68-921b-7e764cc37867"},"_deposit":{"created_by":4,"id":"1939","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"1939"},"status":"published"},"_oai":{"id":"oai:hama-med.repo.nii.ac.jp:00001939","sets":["1:11"]},"author_link":["4929","4930","4931"],"item_3_biblio_info_5":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1989-06-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"6","bibliographicPageEnd":"687","bibliographicPageStart":"683","bibliographicVolumeNumber":"41","bibliographic_titles":[{"bibliographic_title":"日本産科婦人科學會雜誌","bibliographic_titleLang":"ja"}]}]},"item_3_description_9":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Urinastatin (US)によるcisplatin (CDDP)の腎障害保護作用がいかなる薬理効果に基づくものか, すなわち,腎血流量保持作用が主体なのか腎尿細管保護作用によるものかを検討するため家兎を用いて以下の実験を行つた. 使用した薬剤はUS(10,000U/kg, 3時間:1群), メシル酸ガベキサート(2mg/kg/h, 4時間:2群), アプロチニン(5,000U/kg/h, 4時間 : 3群)および塩酸ドパミン(0.3mg/kg/h,4時間:4群)である. 各群5匹ずつ用い輸液量は15ml/kg/hとし, 最初の1時間はprehydration として5%ブドウ糖を, 次の1時間はCDDP 3mg/kgを含んだ3%高張食塩水を,また,次の2時間はposthydrationとして0.9%生理的食塩水を点滴した. 腎機能の指標としてcreatinine clearance (Ccr)値, 尿中arylamidase (AA)活性, 尿中γ-glutamyl transpeptidase(γ-GTP)活性の変化率を測定した. 1. CDDP投与後のCcr値の変化 1, 2群においてはCcr値の変化は認められなかつたが, 3および4群ではCDDP投与1日目が87.5±4.0および72.4±9.8と有意に低下した(p<0.05, p<0.01). 2. CDDP投与後の尿中AA活性,尿中γ-GTP活性の変化 CDDP投与1日目の2, 3, 4群の尿中AA活性は318±101,486±116,672±197であり1群にくらべて2, 3および4群が有意に高値を示したがいずれも一過性の上昇であつた(p<0.05, p<0.01およびp<0.001). これに反し, 1群での尿中AA活性の変動ははとんど認められなかつた. また,尿中γ-GTP活性の変動も尿中AA活性と類似した. 以上より, USのCDDPによる腎障害抑制作用の主体はlysosome酵素の細胞内流出に伴う各種酵素活性をUSが阻害することにより腎尿細管細胞を保護することにあると推定された. また,今回使用したprotease inhibitorのなかではUSがCDDP腎障害保護作用として最良の薬剤であると思われる.","subitem_description_language":"ja","subitem_description_type":"Abstract"}]},"item_3_publisher_6":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"日本産科婦人科学会","subitem_publisher_language":"ja"}]},"item_3_rights_7":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright 日本産科婦人科学会","subitem_rights_language":"ja"},{"subitem_rights":"本文データは学協会の許諾に基づきCiNiiから複製したものである","subitem_rights_language":"ja"}]},"item_3_source_id_19":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"03009165","subitem_source_identifier_type":"ISSN"}]},"item_3_version_type_32":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"小林, 浩","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"大井, 豪一","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"川島, 吉良","creatorNameLang":"ja"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-08-27"}],"displaytype":"detail","filename":"sankafujinka-41_6-683.pdf","filesize":[{"value":"455.0 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"sankafujinka-41_6-683.pdf","url":"https://hama-med.repo.nii.ac.jp/record/1939/files/sankafujinka-41_6-683.pdf"},"version_id":"5fe8ad3b-8a28-42d1-b2da-5a7e87cc66e3"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Cisplatin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Nephrotoxicity","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Urinastatin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Lysosome","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Cisplatin腎障害に対するurinastatinの予防効果に関する家兎実験 : 各種蛋白分解酵素阻害剤等との比較","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Cisplatin腎障害に対するurinastatinの予防効果に関する家兎実験 : 各種蛋白分解酵素阻害剤等との比較","subitem_title_language":"ja"}]},"item_type_id":"3","owner":"4","path":["11"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2013-08-27"},"publish_date":"2013-08-27","publish_status":"0","recid":"1939","relation_version_is_last":true,"title":["Cisplatin腎障害に対するurinastatinの予防効果に関する家兎実験 : 各種蛋白分解酵素阻害剤等との比較"],"weko_creator_id":"4","weko_shared_id":-1},"updated":"2023-08-02T07:20:07.534797+00:00"}